Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
561-580 of 1,307 trials

Chondrosarcoma: Ivosidenib Treatment Study

We are studying the effects of ivosidenib in adults with locally advanced or metastatic chondrosarcoma. This trial aims to see if it improves tumor outcomes and overall survival compared to standard treatments.

Chondrosarcoma>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteOncology

Seasonal Allergic Rhinitis: PQ Grass Treatment for Kids

We are studying a new treatment for children and teens with seasonal allergic rhinitis caused by grass pollen. The goal is to see if it helps reduce symptoms and is safe for long-term use.

Allergic Rhinitis and Conjunctivitis>2 yearsConfirmation phase (III)>20 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyPediatrics

Mechanical Heart Valves: Lower INR Study

We are evaluating if a lower INR range is safer and more effective for patients with bileaflet aortic mechanical valves. This may help reduce bleeding risks associated with current treatment methods.

Aortic Valve Replacement Treatment>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Gabapentin for Nerve Pain in the Leg

We are studying whether gabapentin can reduce leg pain from lower back issues compared to a placebo. The trial also examines its effects on disability, work return, and mental health.

Radicular Leg Pain≤3 monthsConfirmation phase (III)Standard MedicinesNeurologyOrthopedics and Traumatology

Allergic Rhinitis: New Immunotherapy for Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesAllergologyInternal Medicine

Allergic Rhinitis: New Immunotherapy for House Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma6-12 monthsConfirmation phase (III)Investigational MedicinesAllergologyPulmonology

Lupus Nephritis: Ianalumab Study

We are studying whether ianalumab can improve kidney function in people with active lupus nephritis compared to a placebo. This trial also looks at the safety and tolerability of the treatment.

Lupus Nephritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrologyRheumatology

Neuroendocrine Tumors: Personalized vs. Standard RadioTherapy

We are comparing personalized radionuclide therapy with standard treatment for patients with neuroendocrine tumors. The goal is to see which approach is safer and more effective in shrinking tumors and improving quality of life.

Neuroendocrine Tumors6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Multiple Myeloma: Treatment-Free Interval Study

We are exploring whether a treatment-free interval is safe and effective for newly diagnosed multiple myeloma patients receiving a combination of Daratumumab, Lenalidomide, and Dexamethasone. The study aims to compare the effects of continuous treatment versus a break in therapy.

Multiple Myeloma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Metastatic Breast Cancer: FDG-PET/CT vs. Conventional CT

We are studying whether FDG-PET/CT can better monitor treatment response in metastatic breast cancer patients compared to conventional CT. This may help improve survival and quality of life for those involved.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Advanced Melanoma: Vusolimogene Oderparepvec with Nivolumab

We are comparing a new treatment combination for advanced melanoma that has worsened after other therapies. The goal is to see if this combination improves survival and response compared to standard treatment options.

Advanced MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Head and Neck Cancer: Dostarlimab Treatment Study

We are studying whether dostarlimab can improve outcomes for adults with locally advanced head and neck cancer after initial treatment. Participants will receive either the new treatment or a placebo to compare effects.

Squamous Cell Carcinoma of the Head and Neck3-6 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementOncology

HIV Treatment Comparison: Doravirine vs. Dolutegravir

We are studying whether doravirine is as effective as dolutegravir for people newly diagnosed with HIV-1. The trial also examines potential side effects and health changes over time.

HIV Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Crohn's Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn's disease. The study aims to see if it helps reduce symptoms and achieve remission compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Primary IgA Nephropathy: Long-Term Study of Iptacopan

We are evaluating the long-term safety and tolerability of iptacopan in adults with primary IgA nephropathy. This study follows participants who have completed an earlier trial to see how well the treatment works over time.

IgA Nephropathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Acute Progressive Stroke: Norepinephrine Treatment

We are studying whether adding norepinephrine to standard care helps improve recovery in patients with acute progressive perforating artery stroke. The goal is to see if this combination leads to better functional outcomes and reduces complications.

Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Non-Small Cell Lung Cancer: Cemiplimab Immunotherapy Study

We are investigating if continuing cemiplimab treatment helps patients with oligometastatic NSCLC live longer without disease progression after initial therapy. This study compares the effects of cemiplimab to a placebo.

Non-small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Standard MedicinesOncology

Chronic Rhinosinusitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Sedation in Preterm Infants: Dexmedetomidine vs. Midazolam

We are comparing two sedation methods for very preterm infants on mechanical ventilation to see which one helps with extubation time and overall safety. This study will help us understand the best approach for sedation in these vulnerable patients.

Infant Sedation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPediatrics